Navigation Links
RuiYi and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer
Date:5/16/2013

LA JOLLA, Calif. and SHANGHAI, May 16, 2013 /PRNewswire/ -- RuiYi Inc. announced today that it has entered into an exclusive license and collaborative development agreement with Genor BioPharma for the development of RYI-008 in China. RYI-008 is a novel anti-IL-6 monoclonal antibody with a unique pharmacologic profile that has the potential to define a new paradigm in the treatment of autoimmune diseases and cancer.

"RYI-008, with its unprecedented femtamolar potency and amazing long half-life has a therapeutic profile of once monthly, low milligram, subcutaneous dosing," said Paul Grayson , president and CEO of RuiYi. "RYI-008 is a tremendous candidate for this novel development strategy, with approximately 4.1 million biologic treatment naive rheumatoid arthritis patients in China in need of a cost effective therapeutic option.  The team at Genor has deep global development experience and strong commercial, regulatory, and government relationships in China, making them the ideal development partner. We look forward to working with them to deliver novel, breakthrough therapeutics for the Chinese healthcare system."

Joe Zhou , CEO of Genor BioPharma, commented, "The clinical data on IL-6 modulation continues to be extremely favorable in multiple diseases.  The selection by RuiYi and Genor of RYI-008 for development shows a unique understanding of a changing healthcare environment in China where the cost-effective delivery of novel efficacious medicines is of significant importance."

About RYI-008

RYI-008, also known as ARGX-109, is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicated in inflammation and cancer. The antibody was discovered by arGEN-X, Gh
'/>"/>

SOURCE RuiYi Inc.; Genor BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CMC Biologics und RuiYi Enter treffen Vereinbarung zur Entwicklung eines neuartigen monoklonalen Anti-IL-6-Antikörpers
2. CMC Biologics et RuiYi passent un accord pour le développement dun nouvel anticorps monoclonal Anti-IL-6
3. CMC Biologics and RuiYi Enter into an Agreement for Development of a Novel Anti-IL-6 Monoclonal Antibody
4. Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting
5. Callidus Biopharma Announces $4.6 million in Series A Financing to Pursue Orphan Disease Therapies
6. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2013 Financial Results
7. Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013
8. PDL BioPharma to Announce First Quarter 2013 Financial Results on May 9, 2013
9. Rutgers Business School and the Blanche and Irwin Lerner Center will explore trends and issues facing the biopharmaceutical industry at a healthcare symposium, Tuesday, April 30
10. PDL BioPharma Completes Structured Financing and Royalty Transaction with Avinger
11. New PAREXEL Report Defines The Next Generation Of Strategic Partnerships Between CROs And Biopharmaceutical Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- In response to urgent requests from the Deputy Minister of ... , Direct Relief delivered two 10-bed medical tents to ... local health workers who contract Ebola while fighting the outbreak. ... was constructed for foreign health care workers who may contract ... Sierra Leonean health workers. With Sierra ...
(Date:12/22/2014)... MONMOUTH JUNCTION, N.J. , Dec. 22, 2014 ... immunotherapy company marketing its CytoSorb® blood purification technology ... cardiac surgery patients in 28 countries worldwide, today ... Di Russo , MD, FACS, as its Senior ... 2015. Dr. Di Russo ...
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has ... Glucose Market" report to their offering. ... insight focuses on the developments in the self-monitoring blood ... . Reimbursement analysis and the effects of competitive bidding ... 73 SMBG meters have been performed, based on the ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2
... a leader in the pharmaceutical treatment of breathing-control disorders, ... Thomas J. Dietz, Ph.D., as the company,s chairman.  Dr. ... a diversified financial-holdings and services company.   ... and a director of Pacific Growth Equities, LLC, a ...
... YORK, Oct. 26, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0158569/Medical-Imaging-Markets-Contrast-Agents.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging The ... are continuing to grow in significance as ...
Cached Medicine Technology:Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals 2Medical Imaging Markets: Contrast Agents 2Medical Imaging Markets: Contrast Agents 3Medical Imaging Markets: Contrast Agents 4Medical Imaging Markets: Contrast Agents 5Medical Imaging Markets: Contrast Agents 6
(Date:12/26/2014)... Yisrayl Hawkins, Pastor at The House of ... light of the Ferguson, Missouri unrest. Yisrayl starts his letter ... explains why it has only increased. , He continues ... He says there is a very specific reason for mankind ... is a set of rules, or Laws that if followed ...
(Date:12/26/2014)... 2014 “Many people become overwhelmed by ... claim issues and phone calls with insurance companies,” The ... featuring their free eBook on pedestrian and bicycle ... pedestrian and bicycle auto accident claims assures the injured ... of professionally handling their case while they focus on ...
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a ... producing and marketing of a series of induction heating ... new series of induction brazing equipments . , ... induction brazing refers to the joining of two ... heat. The manager says that there are fundamental differences ...
(Date:12/25/2014)... This is a professional and in-depth ... industry with a focus on the Chinese market. The ... the Sterilizers manufacturers and is a valuable source of ... the industry. This report provides a basic overview of ... In this part, the report presents the company profile, ...
(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – Forecast and ... landscape, unmet needs, current pipeline and commercial opportunities in ... which is typically used for treating colorectal cancer. It ... gastric cancer and pancreatic cancer. TS-1 is composed of ... approved in 1999 in Japan for the treatment of ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... , PALM SPRINGS, Calif., Aug. 6 ... with Heritage Provider Networks, is highlighted in a USA Today ... a story titled, "Seniors defend Medicare Plan Obama calls ,wasteful," ... on patients to coordinate care and reduce hospital readmissions." , ...
... , , DETROIT, ... of Michigan (BCBSM), the Michigan Attorney General and the Office of ... the Attorney General,s and Office of Financial and Insurance Regulation,s challenge ... nongroup and group conversion products. , , ...
... , KENILWORTH, N.J., Aug. 6 Schering-Plough ... of its Special Shareholders Meeting being held on Friday, August 7, ... and Merck & Co., Inc. Originating from Boston, the Webcast ... site, www.schering-plough.com . , , ...
... A special four-page ... Dr. James Ioli, chief of podiatry at Harvard-affiliated Brigham and Women,s Hospital in Boston, served as ... Boston (Vocus) August 6, ... stand, serve as shock absorbers when we move, and help propel us forward -- and sometimes ...
... BEIJING and BETHESDA, Md., Aug. 6 /PRNewswire-Asia/ -- ... ("Chindex") (Nasdaq: CHDX ), a leading,independent ... in,the People,s Republic of China, today announced that ... plans to,launch a comprehensive, international-standard oncology program, called ...
... , , EATONTOWN, N.J., Aug. 6 Osteotech, ... field of biologic products for regenerative healing, announced today that its ... Annual Global Growth Conference at the InterContinental Hotel in Boston on ... A live, listen-only webcast of the presentation will be ...
Cached Medicine News:Health News:Desert Oasis Healthcare Featured in USA Today 2Health News:Desert Oasis Healthcare Featured in USA Today 3Health News:Desert Oasis Healthcare Featured in USA Today 4Health News:Blue Cross Blue Shield of Michigan, Michigan Attorney General and Michigan Office of Financial and Insurance Regulation Near Agreement on Rate Increases on Under Age 65 Individual Products 2Health News:Harvard Health Letter Special Section Features the Body's Unsung Marvels: The Feet 2Health News:Chindex International, Inc. Launches World-Class Cancer Treatment Center 2Health News:Chindex International, Inc. Launches World-Class Cancer Treatment Center 3Health News:Chindex International, Inc. Launches World-Class Cancer Treatment Center 4
A highly precise stereotactic radiosurgery system for the treatment of intra-cranial lesions....
The Primus linear accelerator is a fully digital, technologically advanced radiation therapy treatment delivery system. It can be configured for delivery of routine, 3-D conformal or IMRT treatments....
... The cost-effective, proven and reliable ... rates for rapid patient treatment, fastest ... flatness - less than 500 milliseconds, ... highest beam stability, greatest number of ...
The Clinac 2100 C/D family of accelerators are reliable, easy-to-use, flexible and cost-effective systems....
Medicine Products: